(NASDAQ: ATRA) Atara Biotherapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.66%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.69%.
Atara Biotherapeutics's earnings in 2026 is -$14,614,000.On average, 6 Wall Street analysts forecast ATRA's earnings for 2026 to be -$7,402,919, with the lowest ATRA earnings forecast at -$12,680,530, and the highest ATRA earnings forecast at $2,172,175. On average, 6 Wall Street analysts forecast ATRA's earnings for 2027 to be $4,174,203, with the lowest ATRA earnings forecast at $2,046,857, and the highest ATRA earnings forecast at $5,669,866.
In 2028, ATRA is forecast to generate $1,593,472 in earnings, with the lowest earnings forecast at -$4,592,948 and the highest earnings forecast at $12,837,432.